Gardasil is Merck's (MRK) leading vaccine franchise. Total sales for Gardasil in 1Q17 were $532.0 million, a ~41.0% rise over $378.0 million in 1Q16.
Merck stock has risen nearly 16.0% over the last 12 months. Analysts estimate that the stock has a potential to return 10.0% over the next 12 months.
Celldex Therapeutics and Agenus have promising oncology pipelines, but which is the better stock right now?